Scarica l'app Stockscreener
0.65
0.20%
-0.0013
Precedente Chiudi:
$0.6513
Aprire:
$0.652
Volume 24 ore:
59,275
Relative Volume:
0.26
Capitalizzazione di mercato:
$59.97M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-0.7143
EPS:
-0.91
Flusso di cassa netto:
$-31.63M
1 W Prestazione:
+13.52%
1M Prestazione:
-4.54%
6M Prestazione:
-40.91%
1 anno Prestazione:
-67.66%
Intervallo 1D:
$0.6305
$0.652
Intervallo di 1 settimana:
$0.56
$0.6566
Portata 52W:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Confronta CNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.65 | 59.97M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.50 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.24 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.34 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.62 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.45 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-11-25 | Iniziato | D. Boral Capital | Buy |
| 2024-05-16 | Iniziato | Piper Sandler | Overweight |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st
Context Therapeutics Executives Increase Holdings - TradingView
Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha
Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com
Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire
Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN
Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus
FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo
CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire
Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter
Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz
Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics appoints new interim CMO - Investing.com
Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa
Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire
Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com
Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Context Therapeutics Inc Azioni (CNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):